Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients ...

The US FDA has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, ...

Long-awaited joint UK guidelines for asthma have today been finalised, overhauling recommendations to GPs for diagnostics and ...

Anavex Life Sciences (AVXL) stock rises 10% in premarket as company submits EU marketing application for Alzheimer's drug ...

Prostate Treatment Market. The global benign prostatic hyperplasia (BPH) prostate treatment market is set for consistent ...

The "Dementia Associated With Alzheimer's Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Dementia Associated With Alzheimer's Disease - ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

KarXT - Nicola Rizzo Pesci and Andrea Cipriani summarise findings from the EMERGENT-2 trial spotlighting a promising new ...

Vanderbilt University has described muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders ...

Despite previous low sentiment towards Neurocrine’s muscarinic program, this competitive failure provides a chance for a larger market opportunity, assuming Neurocrine successfully navigates the ...